To hear about similar clinical trials, please enter your email below
Trial Title:
Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality
NCT ID:
NCT06258629
Condition:
Hematological Malignancies
Conditions: Official terms:
Neoplasms
Hematologic Neoplasms
Study type:
Observational [Patient Registry]
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Flowcytometry on bone marrow aspiration
Description:
Flowcytometry on bone marrow aspiration
Arm group label:
Case group
Arm group label:
Case group after 6 months
Arm group label:
control group
Summary:
Prognostic value of 'CD200' in hematological malignancies Hematological malignancies
comprise a group of malignant clonal disorders arising from the hematopoietic tissues ,
including leukemia , multiple myeloma , and lymphoma , and they have a high morbidity and
mortality
Criteria for eligibility:
Study pop:
- Control group of healthy individuals.
- Newly diagnosed cases of hematological malignancis.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Newly diagnosed cases of hematological malignancis.
Exclusion Criteria:
- Known cases of hematological malignancies and on treatment.
Gender:
All
Minimum age:
1 Year
Maximum age:
60 Years
Start date:
February 15, 2024
Completion date:
February 6, 2025
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06258629
